Sarepta Therapeutics Inc (NASDAQ:SRPT) has a beta value of 0.84 and has seen 0.36 million shares traded in the recent trading session. The company, currently valued at $6.05B, closed the recent trade at $62.39 per share which meant it gained $0.48 on the day or 0.78% during that session. The SRPT stock price is -177.69% off its 52-week high price of $173.25 and 1.38% above the 52-week low of $61.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.63 million shares traded. The 3-month trading volume is 1.40 million shares.
The consensus among analysts is that Sarepta Therapeutics Inc (SRPT) is Buy stock at the moment, with a recommendation rating of 1.43. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 17 have rated it as a Hold, with 10 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.59.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Sporting 0.78% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SRPT stock price touched $62.39 or saw a rise of 15.63%. Year-to-date, Sarepta Therapeutics Inc shares have moved -48.69%, while the 5-day performance has seen it change -14.39%. Over the past 30 days, the shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have changed -39.34%. Short interest in the company has seen 4.85 million shares shorted with days to cover at 4.51.
Wall Street analysts have a consensus price target for the stock at $182, which means that the shares’ value could jump 65.72% from the levels at last check today. The projected low price target is $165.0 while the price target rests at a high of $202.0. In that case, then, we find that the latest price level in today’s session is -223.77% off the targeted high while a plunge would see the stock gain -164.47% from the levels at last check today.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
The company’s shares have lost -50.04% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 63.94%.
15 analysts offering their estimates for the company have set an average revenue estimate of 693.66M for the current quarter. 16 have an estimated revenue figure of 761.01M for the next ending quarter. Year-ago sales stood 413.46M and 362.93M respectively for this quarter and the next, and analysts expect sales will grow by 67.77% for the current quarter and 63.94% for the next.
Earnings growth for 2025 is a modest 365.79% while over the next 5 years, the company’s earnings are expected to increase by 90.64%.
SRPT Dividends
Sarepta Therapeutics Inc is expected to release its next earnings report on 2025-Feb-25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
Insiders own 4.41% of the company shares, while shares held by institutions stand at 92.26% with a share float percentage of 96.52%. Investors are also buoyed by the number of investors in a company, with Sarepta Therapeutics Inc having a total of 656.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 10.32 million shares worth more than $1.63 billion. As of 2024-06-30, BLACKROCK INC. held 10.9117% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 9.04 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.43 billion and represent 9.6133% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are GROWTH FUND OF AMERICA and iShares Trust-iShares Core S&P Mid-Cap ETF. As of Dec 31, 2024, the former fund manager holds about 3.25% shares in the company for having 3.16 shares of worth $197.39 million while later fund manager owns 3.11 shares of worth $194.3 million as of Feb 28, 2025, which makes it owner of about 3.20% of company’s outstanding stock.
